Regulation of hepatic production of lipoproteins containing apolipoprotein B by ER-associated degradation

Future Lipidology

Volumn 2, Issue 2, 2007, Pages 173-184

  Lapierre, Louis R ^a   McLeod, Roger S ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Apolipoprotein B; Assembly; Chaperone; Proteasome; Translocation

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; APOLIPOPROTEIN B50; CHAPERONE; CHOLESTEROL ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; PROTEASOME; TRIACYLGLYCEROL; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

CYTOSOL; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM; ENZYME REGULATION; FATTY ACID TRANSPORT; GLYCOSYLATION; GOLGI COMPLEX; HUMAN; LIPID PEROXIDATION; LIPOGENESIS; LIVER FUNCTION; MOLECULAR DYNAMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; UBIQUITINATION;

EID: 34249330309     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.2.173     Document Type: Review

References (152)

1. Shelness GS, Ledford AS: Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly. Curr. Opin. Lipidol. 16, 325-332 (2005).
2. Avramoglu RK, Adeli K: Hepatic regulation of apolipoprotein B. Rev. Endocr. Metab. Disord. 5, 293-301 (2004).
3. Hussain MM, Shi J. Dreizen P: Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44, 22-32 (2003).
4. Davidson NO, Shelness GS: Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20, 169-193 (2000).
5. Shelness GS, Ingram MF, Huang XF, DeLozier JA: Apolipoprotein B in the rough endoplasmic reticulum: translation, translocation and the initiation of lipoprotein assembly. J. Nutr. 129, S456-S462 (1999).
6. Davis RA: Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta 1440, 1-31 (1999).
7. Chan L: Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J. Biol. Chem. 267, 25621-25624 (1992).
8. Havel RJ. Kane JP: Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WA, Valle D (Eds). McGraw-Hill, Inc., OH. USA 1853-1885 (1995).
9. Sniderman AD, St Pierre AC, Cantin B et al.: Concordance/ discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am. J. Cardiol. 91, 1173-1177 (2003).
10. Sniderman AD, Furberg CD, Keech A et al: Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 361, 777-780 (2003).
11. Barter PJ, Ballantyne CM, Carmena R et al.: Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. 259, 247-258 (2006).
12. St Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B: Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men. Am. J. Cardiol. 97, 997-1001 (2006).
13. Avramoglu RK, Qiu W, Adeli K: Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front. Biosci. 8, D464-D476 (2003).
14. Phung TL, Roncone A. Jensen KL, Sparks CE, Sparks JD: Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum. J. Biol. Chem. 272, 30693-30702 (1997).
15. Sparks JD, Sparks CE: Insulin regulation of triacylglycerol-rich lipoprotein synthesis and secretion. Biochim. Biophys. Acta 1215. 9-32 (1994).
16. Sparks JD, Sparks CE: Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion. Biochem. Biophys. Res. Commun. 205, 417-422 (1994).
17. Sparks JD, Sparks CE, Bolognino M et al.: Effects of nonketotic streptozotocin diabetes on apolipoprotein B synthesis and secretion by primary cultures of rat hepatocytes. J. Clin. Invest. 82, 37-43 (1988).
18. Gordon DA, Jamil H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochim. Biophys. Acta 1486, 72-83 (2000).
19. Wetterau JR, Lin MC, Jamil H: Microsomal triglyceride transfer protein. Biochim. Biophys. Acta 1345, 136-150 (1997).
20. Rava P, Ojakian GK, Shelness GS. Hussain MM: Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins. J. Biol. Chem. 281, 11019-11027 (2006).
21. Jamil H, Chu CH, Dickson JK Jr et al.; Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells. J. Lipid Res. 39, 1448-1454 (1998).
22. Leung GK, Veniant MM, Kim SK et al.: A deficiency of microsomal triglyceride transfer protein reduces apolipoprotein B secretion. J. Biol. Chem. 275, 7515-7520 (2000).
23. Tietge UJ, Bakillah A, Maugeais C et al.: Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. 40, 2134-2139 (1999).
24. Wang Y, Tran K, Yao Z: The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J. Biol. Chem. 274, 27793-27800 (1999).
25. Raabe M, Veniant MM, Sullivan MA et al.: Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J. Clin. Invest. 103, 1287-1298 (1999).
26. Rustaeus S, Stillemark P, Lindberg K, Gordon D, Olofsson SO: The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells. J. Biol. Chem. 273, 5196-5203 (1998).
27. Wang Y, McLeod RS, Yao Z: Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing apolipoprotein B from McA-RH7777 cells. J. Biol. Chem. 272. 12272-12278 (1997).
28. Zhang YL, Hernandez-Ono A, Ko C et al.: Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J. Biol. Chem. 279, 19362-19374 (2004).
29. Kummrow E, Hussain MM, Pan M. Marsh JB, Fisher EA: Myristic acid increases dense lipoprotein secretion by inhibiting apoB degradation and triglyceride recruitment. J. Lipid Res. 43, 2155-2163 (2002).
30. Zammit VA, Lankester DL: Oleate acutely stimulates the secretion of triacylglycerol by cultured rat hepatocytes by accelerating the emptying of the secretory compartment. Lipids 36, 607-612 (2001).
31. Taghibiglou C, Carpentier A, Van Iderstine SC et al.: Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J. Biol. Chem. 275, 8416-8425 (2000).
32. Sniderman AD, Cianflone K: Substrate delivery as a determinant of hepatic ApoB secretion. Artrioscler. Thromb. 13, 629-636 (1993).
33. Liao W, Ning G: Knockdown of apolipoprotein B, an atherogenic apolipoprotein, in HepG2 cells by lentivirus-mediated siRNA. Biochem. Biophys. Res. Commun. 344, 478-483 (2006).
34. Crooke RM, Graham MJ, Lemonidis KM et al.: An Apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J. Lipid Res. 46, 872-884 (2005).
35. Soutschek J, Akinc A, Bramlage B et al.: Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173-178 (2004).
36. Zimmermann TS, Lee AC, Akinc A et al.: RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
37. Kastelein JJ, Wedel MK, Baker BF et al.: Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 (2006).
38. Sparks JD, Collins HL, Chirieac DV et al.: Hepatic very-low-density lipoprotein and apolipoprotein B production are increased following in vivo induction of betaine-homocysteine S-methyltransferase. Biochem. J. 395, 363-371 (2006).
39. Sidiropoulos KG, Pontrelli L, Adeli K: Insulin-mediated suppression of apolipoprotein B mRNA translation requires the 5′ UTR and is characterized by decreased binding of an insulin-sensitive 110-kDa 5′ UTR RNA-binding protein. Biochemistry 44, 12572-12581 (2005).
40. Pontrelli L, Sidiropoulos KG, Adeli K: Translational control of apolipoprotein B mRNA: regulation via cis elements in the 5′ and 3′ untranslated regions. Biochemistry 43, 6734-6744 (2004).
41. Wang S, McLeod RS, Gordon DA, Yao Z: The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J. Biol. Chem. 271, 14124-14133 (1996).
42. Benoist F, Grand-Perret T: Co-translational degradation of apolipoprotein B100 by the proteasome is prevented by microsomal triglyceride transfer protein. Synchronized translation studies on HepG2 cells treated with an inhibitor of microsomal triglyceride transfer protein. J. Biol. Chem. 272, 20435-20442 (1997).
43. Oyadomari S, Yun C, Fisher EA et al.: Cotranslocational degradation protects the stressed endoplasmic reticulum from protein overload. Cell 126, 727-739 (2006).
44. Schubert U, Anton LC, Gibbs J et al.: Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774 (2000).
45. Schroder M, Kaufman RJ: The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005).
46. Brodsky JL, Gusarova V, Fisher EA: Vesicular trafficking of hepatic apolipoprotein B100 and its maturation to very low-density lipoprotein particles; studies from cells and cell-free systems. Trends Cardiovasc. Med. 14, 127-132 (2004).
47. Fisher EA, Ginsberg HN: Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J. Biol. Chem. 277, 17377-17380 (2002).
48. Ellgaard L, Molinari M, Helenius A: Setting the standards: quality control in the secretory pathway. Science 286, 1882-1888 (1999).
49. Ledford AS, Weinberg RB, Cook VR, Hantgan RR, Shelness GS: Self-association and lipid binding properties of the lipoprotein initiating domain of apolipoprotein B. J. Biol. Chem. 281, 8871-8876 (2006).
50. McLeod RS, Zhao Y, Selby SL, Westerlund J, Yao Z: Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins. J. Biol. Chem. 269, 2852-2862 (1994).
51. Boren J, Graham L, Wettesten M et al.: The assembly and secretion of apoB100-containing lipoproteins in HepG2 cells. ApoB100 is cotranslationally integrated into lipoproteins. J. Biol. Chem. 267, 9858-9867 (1992).
52. Spring DJ, Chen-Liu LW, Chatterton JE, Elovson J, Schumaker VN: Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference. J. Biol. Chem. 267, 14839-14845 (1992).
53. Schumaker VN, Phillips ML, Chatterton JE: Apolipoprotein B and low-density lipoprotein structure: implications for biosynthesis of triglyceride-rich lipoproteins. Adv. Protein Chem. 45, 205-248 (1994).
54. Wang L, Walsh MT, Small DM: Apolipoprotein B is conformationally flexible but anchored at a triolein/water interface: a possible model for lipoprotein surfaces. Proc. Natl Acad. Sci. USA 103, 6871-6876 (2006).
55. Wang L, Small DM: Interfacial properties of amphipathic β-strand consensus peptides of apolipoprotein B at oil/water interfaces. J. Lipid Res. 45, 1704-1715 (2004).
56. Weinberg RB, Cook VR, DeLozier JA, Shelness GS: Dynamic interfacial properties of human apolipoproteins A-IV and B-17 at the air/water and oil/water interface. J. Lipid Res. 41, 1419-1427 (2000).
57. Richardson PE, Manchekar M, Dashti N et al.: Assembly of lipoprotein particles containing apolipoprotein-B: structural model for the nascent lipoprotein particle. Biophys. J. 88, 2789-2800 (2005).
58. Segrest JP, Jones MK, De Loof H, Dashti N: Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42, 1346-1367 (2001).
59. McLeod RS, Wang Y, Wang S et al.: Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment. J. Biol. Chem. 271, 18445-18455 (1996).
60. Rustaeus S, Lindberg K, Boren J, Olofsson SO: Brefeldin A reversibly inhibits the assembly of ApoB containing lipoproteins in McA-RH7777 cells. J. Biol. Chem. 270, 28879-28886 (1995).
61. Boren J. Rustaeus S, Olofsson SO: Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells. J. Biol. Chem. 269, 25879-25888 (1994).
62. Innerarity TL, Boren J, Yamanaka S, Olofsson SO: Biosynthesis of apolipoprotein B48-containing lipoproteins. Regulation by novel post-transcriptional mechanisms. J. Biol. Chem. 271, 2353-2356 (1996).
63. Tran K, Thorne-Tjornsland G, DeLong CJ et al.: Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells. J Biol. Chem. 277, 31187-31200 (2002).
64. Hamilton RL, Wong JS, Cham CM. Nielsen LB, Young SG: Chylomicron-sized lipid particles are formed in the setting of apolipoprotein B deficiency. J. Lipid Res. 39, 1543-1557 (1998).
65. Alexander CA, Hamilton RL, Havel RJ: Subcellular localization of B apoprotein of plasma lipoproteins in rat liver. J. Cell Biol. 69, 241-263 (1976).
66. Rusinol A, Verkade H, Vance JE: Assembly of rat hepatic very low density lipoproteins in the endoplasmic reticulum. J. Biol. Chem. 268, 3555-3562 (1993).
67. Kulinski A, Rustaeus S, Vance JE: Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with apoB, as well as for apoB lipidation. J. Biol. Chem. 277, 31516-31525 (2002).
68. Swift LL: Assembly of very low density lipoproteins in rat liver: a study of nascent particles recovered from the rough endoplasmic reticulum. J. Lipid Res. 36, 395-406 (1995).
69. Patel SB, Grundy SM: Interactions between microsomal triglyceride transfer protein and apolipoprotein B within the endoplasmic reticulum in a heterologous expression system. J. Biol. Chem. 271, 18686-18694 (1996).
70. Leiper JM, Bayliss JD. Pease RJ et al.: Microsomal triglyceride transfer protein, the abetalipoproteinemia gene product, mediates the secretion of apolipoprotein B-containing lipoproteins from heterologous cells. J. Biol. Chem. 269, 21951-21954 (1994).
71. Gordon DA, Jamil H, Sharp D et al.: Secretion of apolipoprotein B-containing lipoproteins from HeLa cells is dependent on expression of the microsomal triglyceride transfer protein and is regulated by lipid availability. Proc. Natl Acad. Sci. USA 91, 7628-7632 (1994).
72. Rusinol AE, Jamil H, Vance JE: In vitro reconstitution of assembly of apolipoprotein B48-containing lipoproteins. J. Biol. Chem. 272, 8019-8025 (1997).
73. Huang XF, Shelness GS: Efficient glycosylation site utilization by intracellular apolipoprotein B. Implications for proteasomal degradation. J. Lipid Res. 40, 2212-2222 (1999).
74. Shelness GS, Morris-Rogers KC, Ingram MF: Apolipoprotein B48-membrane interactions. Absence of transmembrane localization in nonhepatic cells. J. Biol. Chem. 269, 9310-9318 (1994).
75. Herscovitz H, Kritis A, Talianidis I et al.: Murine mammary-derived cells secrete the N-terminal 41% of human apolipoprotein B on high density lipoprotein-sized lipoproteins containing a triacylglycerol-rich core. Proc. Natl Acad. Sci. USA 92, 659-663 (1995).
76. Sellers JA, Shelness GS: Lipoprotein assembly capacity of the mammary tumor-derived cell line C127 is due to the expression of functional microsomal triglyceride transfer protein. J. Lipid Res. 42, 1897-1904 (2001).
77. Pan M, Liang JJ, Fisher EA, Ginsberg HN: The late addition of core lipids to nascent apolipoprotein B100, resulting in the assembly and secretion of triglyceride-rich lipoproteins, is independent of both microsomal triglyceride transfer protein activity and new triglyceride synthesis. J. Biol. Chem. 277, 4413-4421 (2002).
78. Swift LL, Zhu MY, Kakkad B et al.: Subcellular localization of microsomal triglyceride transfer protein. J. Lipid Res. 44, 1841-1849 (2003).
79. Liang JJ, Oelkers P, Guo C et al.: Overexpression of human diacylglycerol acyltransferase 1, acyl-Coa:cholesterol acyltransferase 1, or acyl-CoA:cholesterol acyltransferase 2 stimulates secretion of apolipoprotein B-containing lipoproteins in McA-RH7777 cells. J. Biol. Chem. 279, 44938-44944 (2004).
80. Yamazaki T, Sasaki E, Kakinuma C et al.: Increased very low density lipoprotein secretion and gonadal fat mass in mice overexpressing liver DGAT1. J. Biol. Chem. 280, 21506-21514 (2005).
81. Millar JS, Stone SJ, Tietge UJ et al.: Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J. Lipid Res. 47, 2297-2305 (2006).
82. Adiels M, Taskinen MR, Packard C et al.: Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49, 755-765 (2006).
83. Adiels M, Boren J, Caslake MJ et al.: Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25, 1697-1703 (2005).
84. Zoltowska M, Ziv E, Delvin E et al.: Both insulin resistance and diabetes in Psammomys obesus upregulate the hepatic machinery involved in intracellular VLDL assembly. Arterioscler. Thromb. Vasc. Biol. 24, 118-123 (2004).
85. Asp L, Magnusson B, Rutberg M et al.: Role of ADP ribosylation factor 1 in the assembly and secretion of ApoB-100-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 25, 566-570 (2005).
86. Gilham D, Alam M, Gao W, Vance DE, Lehner R: Triacylglycerol hydrolase is localized to the endoplasmic reticulum by an unusual retrieval sequence where it participates in VLDL assembly without utilizing VLDL lipids as substrates. Mol. Biol. Cell 16, 984-996 (2005).
87. Dolinsky VW, Gilham D, Alam M, Vance DE, Lehner R: Triacylglycerol hydrolase: role in intracellular lipid metabolism. Cell Mol. Life Sci. 61, 1633-1651 (2004).
88. Stillemark-Billton P, Beck C, Boren J, Olofsson SO: Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2. J. Lipid Res. 46, 104-114 (2005).
89. Gallagher JW, Weinberg RB, Shelness GS: ApoA-IV tagged with the ER retention signal KDEL perturbs the intracellular trafficking and secretion of ApoB. J. Lipid Res. 45, 1826-1834 (2004).
90. Lu S, Yao Y, Cheng X et al.: Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size. J. Biol. Chem. 281, 3473-3483 (2006).
91. Magnusson B, Asp L, Bostrom P et al.: Adipocyte differentiation-related protein promotes fatty acid storage in cytosolic triglycerides and inhibits secretion of very low-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 26, 1566-1571 (2006).
92. Yamaguchi J, Gamble MV, Conlon D, Liang JS, Ginsberg HN: The conversion of apoB100 low density lipoprotein/high density lipoprotein particles to apoB100 very low density lipoproteins in response to oleic acid occurs in the endoplasmic reticulum and not in the Golgi in McA-RH7777 cells. J. Biol. Chem. 278, 42643-42651 (2003).
93. Gusarova V, Brodsky JL, Fisher EA: Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. J. Biol. Chem. 278. 48051-48058 (2003).
94. Jones B, Jones EL, Bonney SA et al.: Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat. Genet. 34, 29-31 (2003).
95. Siddiqi SA, Gorelick FS, Mahan JT, Mansbach CM: COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J. Cell Sci. 116, 415-427 (2003).
96. Siddiqi SA, Siddiqi S, Mahan J et al.: The identification of a novel endoplasmic reticulum to Golgi SNARE complex used by the prechylomicron transport vesicle. J. Biol. Chem. 281, 20974-20982 (2006).
97. Siddiqi SA, Mahan J, Siddiqi S, Gorelick FS, Mansbach CM: Vesicle-associated membrane protein 7 is expressed in intestinal ER. J. Cell Sci. 119, 943-950 (2006).
98. Fisher EA, Pan M, Chen X et al.: The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276, 27855-27863 (2001).
99. Yao Z, Tran K, McLeod RS: Intracellular degradation of newly synthesized apolipoprotein B. J. Lipid Res. 38, 1937-1953 (1997).
100. Yeung SJ, Chen SH, Chan L: Ubiquitin-proteasome pathway mediates intracellular degradation of apolipoprotein B. Biochemistry 35, 13843-13848 (1996).
101. Cavallo D, Rudy D, Mohammadi A, Macri J, Adeli K: Studies on degradative mechanisms mediating post-translational fragmentation of apolipoprotein B and the generation of the 70-kDa fragment. J. Biol. Chem. 274, 23135-23143 (1999).
102. Cavallo, D, McLeod RS, Rudy D et al.: Intracellular translocation and stability of apolipoprotein B are inversely proportional to the length of the nascent polypeptide. J. Biol. Chem. 273, 33397-33405 (1998).
103. Adeli K, Macri J, Mohammadi A et al.: Apolipoprotein B is intracellularly associated with an ER-60 protease homologue in HepG2 cells. J. Biol. Chem. 272, 22489-22494 (1997).
104. Adeli K, Wettesten M. Asp L et al.: Intracellular assembly and degradation of apolipoprotein B-100-containing lipoproteins in digitonin-permeabilized HEP G2 cells. J. Biol. Chem. 272, 5031-5039 (1997).
105. Wang CN, Hobman TC, Brindley DN: Degradation of apolipoprotein B in cultured rat hepatocytes occurs in a post-endoplasmic reticulum compartment. J. Biol. Chem. 270, 24924-24931 (1995).
106. Wang CN. McLeod RS, Yao Z, Brindley DN: Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 15, 1481-1491 (1995).
107. Adeli K: Regulated intracellular degradation of apolipoprotein B in semipermeable HepG2 cells. J. Biol. Chem. 269, 9166-9175 (1994).
108. Larsson SL, Skogsberg J, Bjorkegren J: The low density lipoprotein receptor prevents secretion of dense ApoB100-containing lipoproteins from the liver. J. Biol. Chem. 279, 831-836 (2004).
109. Gillian-Daniel DL, Bates PW, Tebon A, Attie AD: Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B. Proc. Natl Acad. Sci. USA 99, 4337-4342 (2002).
110. Twisk J, Gillian-Daniel DL, Tebon A et al.: The role of the LDL receptor in apolipoprotetn B secretion. J. Clin. Invest. 105, 521-532 (2000).
111. Williams KJ, Brocia RW, Fisher EA: The unstirred water layer as a site of control of apolipoprotein B secretion. J. Biol. Chem. 265, 16741-16744 (1990).
112. Tran K, Sun F, Cui Z et al.: Attenuated secretion of very low density lipoproteins from McA-RH7777 cells treated with eicosapentaenoic acid is associated with impaired utilization of triacylglycerol synthesized via phospholipid remodeling. Biochim. Biophys. Acta 1761, 463-473 (2006).
113. Qiu W, Kohen-Avramoglu R, Rashid-Kolvear F et al.: Overexpression of the endoplasmic reticulum 60 protein ER-60 downregulates ApoB100 secretion by inducing its intracellular degradation via a nonproteasomal pathway: evidence for an ER-60-mediated and pCMB-sensitive intracellular degradative pathway. Biochemistry 43, 4819-4831 (2004).
114. Uchiyama S, Shimizu T. Shirasawa T: CuZn-SOD deficiency causes ApoB degradation and induces hepatic lipid accumulation by impaired lipoprotein secretion in mice. J. Biol. Chem. 281. 31713-31719 (2006).
115. Jiang XC, Li Z, Liu R et al.: Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J. Biol. Chem. 280, 18336-18340 (2005).
116. Pan M, Cederbaum AI, Zhang YL et al: Lipid peroxidation and oxidant stress regulate hepatic Apolipoprotein B degradation and VLDL production. J. Clin. Invest. 113, 1277-1287 (2004).
117. Borradaile NM, de Dreu LE, Barrett PH, Huff MW: Inhibition of hepatocyte ApoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J. Lipid Res. 43, 1544-1554 (2002).
118. Theriault A, Wang Q, Van Iderstine SC et al.: Modulation of hepatic lipoprotein synthesis and secretion by taxifolin, a plant flavionoid. J. Lipid Res. 41, 1969-1979 (2000).
119. Wilcox LJ, Borradaile NM, de Dreu LE. Huff MW: Secretion of hepatocyte ApoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J. Lipid Res. 42, 725-734 (2001).
120. Borradaile NM, de Dreu LE, Barrett PH. Behrsin CD, Huff MW: Hepatocyte ApoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry 42, 1283-1291 (2003).
121. Mohammadi A, Macri J, Newton R et al.: Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 18, 783-793 (1998).
122. Chong T, Naples M, Federico L et al.: Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia. Atherosclerosis 185, 21-31 (2006).
123. Carpentier A, Patterson BW, Uffelman KD, Salit I, Lewis GF: Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis 178, 165-172 (2005).
124. Petit JM, Duong M, Florentin E et al.: Increased VLDL-ApoB and IDL-ApoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable Isotope kinetic study. J. Lipid Res. 44, 1692-1697 (2003).
125. Riddle TM, Schildmeyer NM, Phan C, Fichtenbaum CJ, Hui DY: The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J. Lipid Res. 43, 1458-1463 (2002).
126. Liang JS, Distler O, Cooper DA et al.: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med. 7, 1327-1331 (2001).
127. Avramoglu RK, Basciano H, Adeli K: Lipid and lipoprotein dysregulation in insulin resistant states. Clin. Chim. Acta 368, 1-19 (2006).
128. Yamaguchi J, Conlon DM, Liang JJ. Fisher EA, Ginsberg HN: Translocation efficiency of apolipoprotein B is determined by the presence of β-sheet domains, not pause transfer sequences. J. Biol. Chem. 281, 27063-27071 (2006).
129. Lapierre LR, Currie DL, Yao Z, Wang J, McLeod RS: Amino acid sequences within the β1 domain of human apolipoprotein B can mediate rapid intracellular degradation. J. Lipid Res. 45, 366-377 (2004).
130. Liang JS, Wu X, Jiang H et al.: Translocation efficiency, susceptibility to proteasomal degradation, and lipid responsiveness of apolipoprotein B are determined by the presence of β-sheet domains. J. Biol. Chem. 273, 35216-35221 (1998).
131. Michell DM, Zhou M, Pariyarath R et al.: Apoprotein B100 has a prolonged interaction with the translocon during which its lipidation and translocation change from dependence on the microsomal triglyceride transfer protein to Independence. Proc. Natl Acad. Sa USA 95, 14733-14738 (1998).
132. Fisher EA, Zhou M. Mitchell DM et al.: The degradation of apolipoprotein B100 is mediated by the ubiquitin-proteasome pathway and involves heat shock protein 70. J. Biol. Chem. 272, 20427-20434 (1997).
133. Zhou M, Wu X, Huang LS, Ginsberg HN: Apoprotein B100, an inefficiently translocated secretory protein, is bound to the cytosolic chaperone, heat shock protein 70. J. Biol. Chem. 270, 25220-25224 (1995).
134. Liao W. Yeung SC, Chan L: Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplasmic reticulum. J. Biol. Chem. 273, 27225-27230 (1998).
135. Borchardt RA, Davis RA: Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion. J. Biol. Chem. 262, 16394-16402 (1987).
136. Cardozo C, Wu X, Pan M, Wang H, Fisher EA: The inhibition of microsomal triglyceride transfer protein activity in rat hepatoma cells promotes proteasomal and nonproteasomal degradation of apoprotein B100. Biochemistry 41, 10105-10114 (2002).
137. Taghibiglou C, Rudy D, Van Iderstine SC et al.: Intracellular mechanisms regulating ApoB-containing lipoprotein assembly and secretion in primary hamster hepatocytes. J. Lipid Res. 41, 499-513 (2000).
138. Glickman MH, Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (2002).
139. Voges D, Zwickl P, Baumeister W: The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015-1068 (1999).
140. Ye Y, Meyer HH, Rapoport TA: Function of the p97-Ufd1 -Np14 complex in retrotranslocation from the ER to the cytosol: dual recognition of nonubiquitinated polypeptide segments and polyubiquitin chains. J. Cell Biol. 162, 71-84 (2003).
141. Ye Y, Meyer HH, Rapoport TA: The AAA ATPase Cdc48/p97 and its partners transport proteins from the ER into the cytosol. Nature 414, 652-656 (2001).
142. Hegde RS, Voigt S, Rapoport TA, Lingappa VR: TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum. Cell 621-631 (1998).
143. Ye Y, Shibata Y, Yun C. Ron D, Rapoport TA: A membrane protein complex mediates retro-translocation from the ER lumen into the cytosol. Nature 429, 841-847 (2004).
144. Ohsaki Y, Cheng J, Fujita A, Tokumoto T, Fujimoto T: Cytoplasmic lipid droplets are sites of convergence of proteasomal and autophagic degradation of apolipoprotein B. Mol. Biol. Cell 17, 2674-2683 (2006).
145. Du EZ, Fleming JF, Wang SL, Spitsen GM, Davis RA: Translocation-arrested apolipoprotein B evades proteasome degradation via a sterol-sensitive block in ubiquitin conjugation. J. Biol. Chem. 274, 1856-1862 (1999).
146. Liang JS, Kim T, Fang S et al.: Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J. Biol. Chem. 278, 23984-23988 (2003).
147. Liao W, Chang BH, Mancini M. Chan L: Ubiquitin-dependent and -independent proteasomal degradation of ApoB associated with endoplasmic reticulum and Golgi apparatus, respectively, in HepG2 cells. J. Cell Biochem. 89, 1019-1029 (2003).
148. Zhang J, Herscovitz H: Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B. J. Biol. Chem. 278, 7459-7468 (2003).
149. Qiu W. Avramoglu RK, Rutledge AC, Tsai J, Adeli K: Mechanisms of glucosamine-induced suppression of the hepatic assembly and secretion of apolipoprotein B-100-containing lipoproteins. J. Lipid Res. 47, 1749-1761 (2006).
150. Qiu W, Kohen-Avramoglu R, Mhapsekar S et al.: Glucosamine-induced endoplasmic reticulum stress promotes ApoB100 degradation: evidence for Grp78-mediated targeting to proteasomal degradation. Arterioscler. Thromb. Vasc. Biol. 25, 571-577 (2005).
151. Hevi S, Chuck SL: Ferritins can regulate the secretion of apolipoprotein B. J. Biol. Chem. 278, 31924-31929 (2003).
152. Brown MS, Goldstein JL: Biomedicine. Lowering LDL - not only how low, but how long? Science 311, 1721-1723 (2006).